{"id":"W4313729039","doi":"10.1093/bjd/ljac021","title":"Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial","year":2023,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dermatrials Research","funders":"Cilag; LEO Pharma; Novo Nordisk; Galderma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Sanofi Genzyme; Incyte; Dermira; UCB Pharma; Sun Pharma; Regeneron Pharmaceuticals; Celgene; Samsung; Valeant Pharmaceuticals International; Sanofi; Amgen; Meiji Seika Pharma; Pfizer","keywords":"Open label; Randomized controlled trial; Plaque psoriasis; Medicine; Term (time); Psoriasis; Extension (predicate logic); Surgery; Dermatology; Computer science","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001432658,0.0002622871,0.002226182,0.00007063031,0.000330044,0.0001134569,0.00052548,0.0003239291,0.00003002436],"category_scores_gemma":[0.001401304,0.0001328636,0.000197828,0.0002044858,0.0005982377,0.0001723437,0.0002023621,0.0004329348,0.000003997332],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001950239,"about_ca_system_score_gemma":0.0001656112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001115425,"about_ca_topic_score_gemma":0.0005013925,"domain_scores_codex":[0.9936463,0.004111697,0.001432636,0.0003520826,0.000144156,0.0003131322],"domain_scores_gemma":[0.9884892,0.01003334,0.0009600309,0.0003136658,0.000167648,0.00003619132],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9859824,0.0003996552,0.0002885824,0.000001865285,0.001927356,0.0002339153,0.002224658,0.000007688957,0.00002851642,0.00006162388,0.002792667,0.006051058],"study_design_scores_gemma":[0.976956,0.0004030598,0.01976068,0.0002182024,0.0009663423,0.0005529902,0.0002625092,0.00001028121,0.00008295648,0.0002762081,0.0003550785,0.0001556676],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841254,0.006534798,0.00001481,0.003477683,0.001132778,0.0040799,0.0005874691,0.00001114516,0.00003595768],"genre_scores_gemma":[0.9956694,0.003361646,0.00005366881,0.000401384,0.0001142604,0.00007740132,0.0002475923,0.00002236804,0.00005224432],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0194721,"threshold_uncertainty_score":0.5418022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01857848623439885,"score_gpt":0.2485509443510118,"score_spread":0.229972458116613,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}